Meta AnalysisID 4901
斑蝥酸钠维生素B6注射液联合铂类化疗治疗晚期非小细胞肺癌：一项Meta分析与系统评价
CRD42018086377
Does disodium cantharidinate and vitamin B6 injection adjunct with platinum-based chemotherapy for the treatment of IPF have definite clinical efficacy?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4901
- Evidence Id
- 13459
- Core Evidence Id
- 13459
- Source Meta Analysis Id
- 4874
- Herb2 Meta Analysis Id
- HBMA004874
- Crd Id
- CRD42018086377
- Title
- Disodium cantharidinate and vitamin B6 injection adjunct with platinum-based chemotherapy for the treatment of advanced non-small-cell lung cancer: a meta-analysis and systematic review
- Review Question
- Does disodium cantharidinate and vitamin B6 injection adjunct with platinum-based chemotherapy for the treatment of IPF have definite clinical efficacy?
- Study Type Included
- Randomised controlled clinical trials to assess the beneficial effects of the treatments.
- Condition Being Studied
- Non-small-cell lung cancer
- Participant
- Adults with non-small-cell lung cancer (as diagnosed using any recognised diagnostic criteria).
- Animal
- Human Disease Modelled
- Intervention
- Combined application of disodium cantharidinate and vitamin B6 injection and treatment with platinum-based chemotherapy.
- Comparator Control
- Treatment with platinum-based chemotherapy.
- Main Outcome
- Objective Tumor Response. Measures of effect Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
- Outcome Measure
- Additional Outcome
- Improved KPS. Measures of effect QOL improved: KPS incresaed more than 10 points. QOL declined: KPS decresaed more than 10 points.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Injections; Lung Neoplasms; Platinum; Treatment Outcome; Vitamin B 6
- Contact
- Zhichao Wang [email protected]
- Organisational Affiliation
- Nanjing University of Chinese Medicine http://www.njutcm.edu.cn/
- Funding Source
- National Natural Science Foundation of China
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2018-01-17
- Registration Date
- 2018-01-25
- Anticipated Start Date
- 2018-01-01
- Anticipated Completion Date
- 2018-03-01
- Title Cn
- 斑蝥酸钠维生素B6注射液联合铂类化疗治疗晚期非小细胞肺癌：一项Meta分析与系统评价
- Title En
- Disodium cantharidinate and vitamin B6 injection adjunct with platinum-based chemotherapy for the treatment of advanced non-small-cell lung cancer: a meta-analysis and systematic review
- Bilingual Status
- complete